Complete abstract information will be provided to the CMSC Annual Meeting attendees on May 28, 2023.
| Year | ID | Type | Category | Title | Authors |
|---|
| 2017 | NI04 | Poster | Non-imaging Biomarkers |
Quantitative Motor Performance Is Indicative of Impairments in Specific Cognitive Domains Among Persons with Multiple Sclerosis |
John Vollmer, n/a1, Mareena Atalla, BS1, Manon Nitta, n/a1 and Nora E Fritz, PhD, PT, DPT, NCS1,2, (1)Neuroimaging and Neurorehabilitation Laboratory, Wayne State University, Detroit, MI, (2)Physical Therapy, Wayne State University, Detroit, MI |
| 2017 | NI05 | Poster | Non-imaging Biomarkers |
Vitamin A and Race in MS Patients Supplemented for Vitamin D |
Jason Ledesma, BS1, Padma Priya Puttagunta, MD2, Kristen Berube, BS2 and Bijal Mehta, MD, MPH3, (1)Neurology, LA BIOMED, Torrance, CA, (2)Neurology, LA Biomed, Torrance, CA, (3)Neurology, Harbor-UCLA Medical Center, Torrance, CA |
| 2017 | NP01 | Poster | Neuropathology and Pathogenesis |
Comparison of Etomoxir, a Lipid Metabolism Blocker, and Interferon-Beta Treatment on Antibody Recognition of Brain Proteins in Multiple Sclerosis |
Anne S Moerkholt, MSc1, Kenneth Kastaniegaard, MSc1, Michael Trabjerg, MD1, Gopana Gopalasingam, BSc1, Wanda Niganze, BSc1, Michal K Oklinski, Postdoc2, Agnete Larsen, PhD, Associate Prof.3, Jette GK Nieland, MSc4, Allan Stensballe, PhD, Associate Prof.5, Soren Nielsen, MD, Prof.1 and John D Nieland, PhD, Associate Prof.5, (1)Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, (2)Health Science and Technology, Aalborg University, Aalborg, Denmark, (3)Department of Biomedicine, Aarhus University, Aarhus, Denmark, (4)Meta-IQ ApS, Aarhus, Denmark, (5)Department of Health Science and Technologies, Aalborg University, Aalborg, Denmark |
| 2017 | NP02 | Poster | Neuropathology and Pathogenesis |
Characterization of Humane Autoantibody Response to Brain Proteins in Multiple Sclerosis Patients |
Anne S Moerkholt, MSc1, Kenneth Kastaniegaard, MSc1, Allan Stensballe, PhD, Associate Prof.2, Soren Nielsen, MD, Prof.1 and John D Nieland, PhD, Associate Prof.2, (1)Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, (2)Department of Health Science and Technologies, Aalborg University, Aalborg, Denmark |
| 2017 | NP03 | Poster | Neuropathology and Pathogenesis |
Effect of Teriflunomide on Lymphocyte Counts and Infections over the Long-Term in the TEMSO Extension Study |
Giancarlo Comi, MD1, Aaron E Miller, MD2, Myriam Benamor, MD3, Philippe Truffinet, MD3, Karthinathan Thangavelu, PhD4 and Mark S Freedman, MD5, (1)University Vita-Salute San Raffaele, Milan, Italy, (2)Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New York, NY, (3)Sanofi Genzyme, Chilly-Mazarin, France, (4)Sanofi Genzyme, Cambridge, MA, (5)University of Ottawa and the Ottawa Hospital Research Institute, Ottowa, ON, Canada |
| 2017 | NP04 | Poster | Neuropathology and Pathogenesis |
A Case of an Adult with Acute Disseminated Encephalomyelitis with Optic Neuritis Associated to Anti-Mog Antibody |
Iris Vanessa Marin Collazo, M.D., Multiple Sclerosis Neurology, Mayo Clinic, Rochester, MN and Orhun Kantarci, M.D., Neurology, Mayo Clinic, Rochester, MN |
| 2017 | NP05 | Poster | Neuropathology and Pathogenesis |
Modifications like Citrulination and MDA Adducts, Lipidation and the Immune System; A Menage a Trois Gone Wrong in Multiple Sclerosis |
| 2017 | NP06 | Poster | Neuropathology and Pathogenesis |
Expanding the Concept of Paraneoplastic Neuromyelitis Optica: A Cohort Description with Histological Staining |
Philippe Beauchemin, MD1, C. Blake Gilks, MD2, Raffaele Iorio, MD, PHD3, Anthony Traboulsee, MD4, Thalia Field, MD, MHSc5 and Robert Carruthers, MD4, (1)UBC MS Clinic, Vancouver, BC, Canada, (2)Dept of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, (3)Istituto di Neurologia Università Cattolica del Sacro Cuore, Roma, Italy, (4)Neurology, University of British Columbia, Vancouver, BC, Canada, (5)University of British Columbia, Vancouver, BC, Canada |
| 2017 | PF01 | Poster | Psychosocial Factors |
The Influence of Psychodrama in Cognition and Social Skills in Patients with Multiple Sclerosis |
| 2017 | PF02 | Poster | Psychosocial Factors |
The Relationship Between Anxiety and Illness Intrusiveness in Multiple Sclerosis |
Caroline Altaras, B.A.1, Nicholas A Vissicchio, B.A.1, Jennifer Miller, B.A.2, Shonna Schneider, B.A.2, Shaina Shagalow, B.A.2, Amanda A Parker, B.S.2 and Frederick W Foley, Ph.D.3, (1)Yeshiva University Ferkauf Graduate School of Psychology, Bronx, NY, (2)Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, (3)School of Psychology, Yeshiva University, New York, NY |
| 2017 | PF03 | Poster | Psychosocial Factors |
Impact of Keeping Health and Other Types of Insurance in MS |
Deborah M MIller, PhD, LISW1, Sarah M Planchon, PhD, CCRP2, Carol Musil, PhD, RN, FAAN, FGSA3, Sarah Givens, B.S.3, Mary Beth Mercer, MPH4, Hollie Schmidt, MS5 and Stacey S Cofield, PhD6, (1)Mellon Center, Cleveland Clinic, Cleveland, OH, (2)The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, (3)Case Western Reserve University, Cleveland, OH, (4)Bioethics, Cleveland Clinic, Cleveland, OH, (5)Accelerated Cure Project for MS, Waltham, MA, (6)Biostatistics, University of Alabama at Birmingham, Birmingham, AL |
| 2017 | PF04 | Poster | Psychosocial Factors |
Sedentary Behavior in People with MS: Impact on Cognitive Functioning |
Heena Manglani, B.A., Alisha Janssen, M.A. and Ruchika S. Prakash, Ph.D., Department of Psychology, The Ohio State University, Columbus, OH |
| 2017 | PF05 | Poster | Psychosocial Factors |
Cognitive Impairment As a Risk Factor for Suicidal Ideation in Multiple Sclerosis |
Jeffrey G Portnoy, B.A.1,2, Eliana Pasternak, M.A.1, Shonna Schneider, B.A.1, Shaina Shagalow, B.A.1 and Frederick W Foley, Ph.D.1,2, (1)Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, (2)Holy Name Medical Center, Teaneck, NJ |
| 2017 | PF05 | Poster | Psychosocial Factors |
Cognitive Impairment As a Risk Factor for Suicidal Ideation in Multiple Sclerosis |
Jeffrey G Portnoy, B.A.1,2, Eliana Pasternak, M.A.1, Shonna Schneider, B.A.1, Shaina Shagalow, B.A.1 and Frederick W Foley, Ph.D.1,2, (1)Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, (2)Holy Name Medical Center, Teaneck, NJ |
| 2017 | PF06 | Poster | Psychosocial Factors |
Fatigue Is Associated with Suicidal Thoughts in Multiple Sclerosis |
Jeffrey G Portnoy, B.A.1,2, Shaina Shagalow, B.A.2, Eliana Pasternak, M.A.2, Shonna Schneider, B.A.2 and Frederick W Foley, Ph.D.1,2, (1)Holy Name Medical Center, Teaneck, NJ, (2)Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY |
| 2017 | PF06 | Poster | Psychosocial Factors |
Fatigue Is Associated with Suicidal Thoughts in Multiple Sclerosis |
Jeffrey G Portnoy, B.A.1,2, Shaina Shagalow, B.A.2, Eliana Pasternak, M.A.2, Shonna Schneider, B.A.2 and Frederick W Foley, Ph.D.1,2, (1)Holy Name Medical Center, Teaneck, NJ, (2)Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY |
| 2017 | PF08 | Poster | Psychosocial Factors |
Availability and Sources of Health and Other Types of Insurance in MS |
Sarah M Planchon, PhD, CCRP1, Stacey S Cofield, PhD2, Carol Musil, PhD, RN, FAAN, FGSA3, Sarah Givens, B.S.3, Hollie Schmidt, MS4, MaryBeth Mercer, MPH5 and Deborah M MIller, PhD, LISW6, (1)Mellen Center, Cleveland Clinic, Cleveland, OH, (2)Biostatistics, University of Alabama at Birmingham, Birmingham, AL, (3)Case Western Reserve University, Cleveland, OH, (4)Accelerated Cure Project for MS, Waltham, MA, (5)Bioethics, Cleveland Clinic, Cleveland, OH, (6)Mellon Center, Cleveland Clinic, Cleveland, OH |
| 2017 | PF08 | Poster | Psychosocial Factors |
Availability and Sources of Health and Other Types of Insurance in MS |
Sarah M Planchon, PhD, CCRP1, Stacey S Cofield, PhD2, Carol Musil, PhD, RN, FAAN, FGSA3, Sarah Givens, B.S.3, Hollie Schmidt, MS4, MaryBeth Mercer, MPH5 and Deborah M MIller, PhD, LISW6, (1)Mellen Center, Cleveland Clinic, Cleveland, OH, (2)Biostatistics, University of Alabama at Birmingham, Birmingham, AL, (3)Case Western Reserve University, Cleveland, OH, (4)Accelerated Cure Project for MS, Waltham, MA, (5)Bioethics, Cleveland Clinic, Cleveland, OH, (6)Mellon Center, Cleveland Clinic, Cleveland, OH |
| 2017 | QL01 | Poster | Quality of Life Outcomes |
Evaluation of Sexual Dysfunctions in Men with Multiple Sclerosis |
| 2017 | QL02 | Poster | Quality of Life Outcomes |
PR MS Registry: MS Disability Survey |
Angel Chinea, MD1, Ivonne Vicente, MD2, Cristina M Rubi, BS2, Guillermo G Garcia, BS3, Astrid Diaz, BS3, Ana Rivera, BS3 and Natalia Hernandez, BS3, (1)San Juan Multiple Sclerosis Center, San Juan, PR, (2)San Juan Multiple Sclerosis Center, Guaynabo, PR, (3)San Juan MS Center, Guaynabo, PR |
| 2017 | QL03 | Poster | Quality of Life Outcomes |
Anne Gilbert, BS, Programs, Can Do Multiple Sclerosis, Avon, CO |
| 2017 | QL04 | Poster | Quality of Life Outcomes |
Outcomes in the African-American Subpopulation from the Phase 4 Teri-PRO Study of Teriflunomide |
Annette Okai, MD1, Bhupendra Khatri, MD2, Keith R Edwards, MD3, Steve Cavalier, MD4, Pascal Rufi, MD5, Soman Chowdhury, MSc6, Myriam Benamor, MD5, Ralf Gold, MD7 and Patricia K Coyle, MD8, (1)Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, (2)The Regional MS Center, Center for Neurological Disorders at Wheaton Franciscan Healthcare, Milwaukee, WI, (3)Multiple Sclerosis Center of Northeastern New York, Latham, NY, (4)Sanofi Genzyme, Cambridge, MA, (5)Sanofi Genzyme, Chilly-Mazarin, France, (6)Cytel Statistical Software and Services, Pune, Maharashtra, India, (7)St Josef Hospital, Ruhr University Bochum, Bochum, Germany, (8)Stony Brook University, Stony Brook, NY |
| 2017 | QL05 | Poster | Quality of Life Outcomes |
What 60,000 People with MS Are Saying about MS DMTs, and What It Tells Us about Opportunities to Improve MS Care |
Terrie Livingston, PharmD1, Eric Peacock, CEO2 and Beth Schneider, Research Director2, (1)Biogen Idec, Cambridge, MA, (2)MyHealthTeams, San Francisco, CA |
| 2017 | QL06 | Poster | Quality of Life Outcomes |
What Matters in MS – a Quantitative Survey of People Living with MS |
Terrie Livingston, PharmD1, Eric Peacock, CEO2, Beth Schneider, Research Director2 and Heather Lapidus Glassner, Research Director2, (1)Biogen Idec, Cambridge, MA, (2)MyHealthTeams, San Francisco, CA |
| 2017 | QL07 | Poster | Quality of Life Outcomes |
Patient-Reported Outcomes Are the Strongest Predictors of Disability Progression in Intramuscular Interferon Beta-1a Users in the NYS MS Consortium |
Bianca Weinstock-Guttman, MD1,2,3, Caila B Vaughn, PhD, MPH1,2,3, Katelyn S. Kavak, MS1,2,3, Shulian Shang, PhD4 and Crystal Watson, MS4, (1)Jacobs MS Center of Treatment and Research, Buffalo, NY, (2)New York State Multiple Sclerosis Consortium, Buffalo, NY, (3)Department of Neurology, University at Buffalo, Buffalo, NY, (4)Biogen, Cambridge, MA |
| 2017 | QL07 | Poster | Quality of Life Outcomes |
Patient-Reported Outcomes Are the Strongest Predictors of Disability Progression in Intramuscular Interferon Beta-1a Users in the NYS MS Consortium |
Bianca Weinstock-Guttman, MD1,2,3, Caila B Vaughn, PhD, MPH1,2,3, Katelyn S. Kavak, MS1,2,3, Shulian Shang, PhD4 and Crystal Watson, MS4, (1)Jacobs MS Center of Treatment and Research, Buffalo, NY, (2)New York State Multiple Sclerosis Consortium, Buffalo, NY, (3)Department of Neurology, University at Buffalo, Buffalo, NY, (4)Biogen, Cambridge, MA |
| 2017 | QL07 | Poster | Quality of Life Outcomes |
Patient-Reported Outcomes Are the Strongest Predictors of Disability Progression in Intramuscular Interferon Beta-1a Users in the NYS MS Consortium |
Bianca Weinstock-Guttman, MD1,2,3, Caila B Vaughn, PhD, MPH1,2,3, Katelyn S. Kavak, MS1,2,3, Shulian Shang, PhD4 and Crystal Watson, MS4, (1)Jacobs MS Center of Treatment and Research, Buffalo, NY, (2)New York State Multiple Sclerosis Consortium, Buffalo, NY, (3)Department of Neurology, University at Buffalo, Buffalo, NY, (4)Biogen, Cambridge, MA |
| 2017 | QL08 | Poster | Quality of Life Outcomes |
National MS Society and Can Do MS Webinar & Telelearning Series |
Doris Lill, BS, Advocacy, Services and Research, National Multiple Sclerosis Society, Denver, CO and Anne Lee Gilbert, BS, Can Do MS, Avon, CO |
| 2017 | QL09 | Poster | Quality of Life Outcomes |
Impact of Sleep Disorders on Depression and Health-Related Quality of Life in Multiple Sclerosis |
Emily K White, Ph.D.1, Amy Sullivan, Psy.D.1 and Michelle Drerup, Psy.D., C.BSM2, (1)The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, (2)Sleep Disorders Center, Cleveland Clinic, Cleveland, OH |
| 2017 | QL10 | Poster | Quality of Life Outcomes |
A New Machine Learning Approach to Predict Disease Course in Multiple Sclerosis |
Giampaolo Brichetto, MD, PhD1, Samuele Fiorini, PhD2, Michela Ponzio, PhD1, Annalisa Barla, PhD2, Alessandro Verri, PhD2 and Andrea Tacchino, PhD1, (1)Scientific Research Area, Italian MS Society, Genoa, Italy, Genova, Italy, (2)DIBRIS, University of Genoa, Genova, Italy |
| 2017 | QL11 | Poster | Quality of Life Outcomes |
Heather M Hawks, MS1, Elizabeth W. Triche, PhD2, Jennifer A. Ruiz, DPT1, Kayla M. Olson, MA1 and Albert C. Lo, MD, PhD1, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, (2)Department of Epidemiology, Brown University, Providence, RI |
| 2017 | QL12 | Poster | Quality of Life Outcomes |
Integrating the Patient Voice into Continuing Medical Education Results in Improved Clinician Knowledge and Performance in Multiple Sclerosis |
Jamie Reiter, PhD, Jan Perez, CHCP, Sharon Tordoff, CHCP and Whitney Faler, MPA, CME Outfitters, LLC, Bethesda, MD |
| 2017 | QL13 | Poster | Quality of Life Outcomes |
Patient-Reported Treatment Satisfaction in Treatment-Naive and -Experienced RRMS Patients Receiving Oral Disease-Modifying Therapies |
Julia Morawski, MSc1, Fred Cox, PhD1, Soman Chowdhury, MSc2 and Karthinathan Thangavelu, PhD1, (1)Sanofi Genzyme, Cambridge, MA, (2)Cytel Statistical Software and Services, Pune, Maharashtra, India |
| 2017 | QL14 | Poster | Quality of Life Outcomes |
Effect of Coexisting Autoimmune Disorders on Clinical Outcome in Multiple Sclerosis Patients: An Analysis from National Inpatient Database |
Malik M Adil, MD and Bridget A Bagert, MD, Neurology, Ochsner Clinic Foundation, New Orleans, LA |
| 2017 | QL15 | Poster | Quality of Life Outcomes |
Understanding Concepts Important to Natalizumab Patients: A Qualitative Interview Study |
Margaret Cho, MPH1, Ellen S Lathi, MD2, John Foley, MD3, Ben W Thrower, MD4, Vivien Ong, MPH1, Kellee Howard, MA, MSc1, Huan Wang, BS, BA1, Jie Ting, PhD, MSPH5, Crystal Watson, MS5 and Sarah Naoshy, MPH5, (1)ICON, San Francisco, CA, (2)The Elliot Lewis Center for Multiple Sclerosis Care, Brighton, MA, (3)Rocky Mountain MS Research Group, Salt Lake City, UT, (4)Shepherd Center, Atlanta, GA, (5)Biogen, Cambridge, MA |
| 2017 | QL16 | Poster | Quality of Life Outcomes |
Correlating Blindness with Patient Reported Outcomes, Demographics, and Performance in Nmo |
| 2017 | QL17 | Poster | Quality of Life Outcomes |
A Five-Year Study Evaluating Hand Grip Strength As an Assessment Tool for Multiple Sclerosis Disease Progression |
Meghan C Romba, MD1, Kathryn Fitzgerald, ScD2, Moira Baynes, RN3, Peter A Calabresi, MD3 and Kathleen M Zackowski, PhD, OT3, (1)Neuroimmunology, Johns Hopkins Hospital, Baltimore, MD, (2)Neurology, Johns Hopkins Hospital, Baltimore, MD, (3)Neurology, Johns Hopkins University, Baltimore, MD |
| 2017 | QL18 | Poster | Quality of Life Outcomes |
Can Presenting Symptoms be Associated with Long-Term Disease Severity in Patients with MS |
Padma Priya Puttagunta, MD1, Jason Ledesma, BS2, Kristen Berube, BS1 and Bijal Mehta, MD, MPH3, (1)Neurology, LA Biomed, Torrance, CA, (2)Neurology, LA BIOMED, Torrance, CA, (3)Neurology, Harbor-UCLA Medical Center, Torrance, CA |
| 2017 | QL19 | Poster | Quality of Life Outcomes |
The Association Between Digitally Assessed Patient-Reported Outcomes and In-Clinic Assessments in the FLOODLIGHT Study in Multiple Sclerosis |
Patricia Mulero, MD1, Luciana Midaglia, MD1, Xavier Montalban, MD, PhD2, Jennifer Graves, MD, PhD, MAS3, Stephen L Hauser, MD3, Laura Julian, PhD4, Mike Baker, BSc, MSc5, Jan Schadrack, MD5, Christian Gossens, PhD, MBA5, Fiona Mc Dougall, PhD, ClinPsyD6, Alf Scotland, MSc5, Yang-Ping Zhang Schaerer, PhD5, Andrew Creagh, BA, BAI, MAI5, Shibeshih Belachew, MD, PhD5 and Michael Lindemann, MD, PhD5,7, (1)Multiple Sclerosis Center of Catalonia, Hospital Vall d’Hebron University, Barcelona, Spain, (2)Vall d’Hebron University Hospital, Barcelona, Spain, (3)University of California, San Francisco, San Francisco, CA, (4)Genentech Inc., South San Francisco, CA, (5)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (6)Roche Products Limited, Welwyn Garden City, United Kingdom, (7)Baden-Wuerttemberg Cooperative State University, Loerrach, Germany |
| 2017 | QL20 | Poster | Quality of Life Outcomes |
Impact of Betaconnect Auto-Injector on Patient Adherence of Betaseron Therapy |
Mark Rametta, D.O., FACOI, FACP1, Rebecca Germino, MA2, Kim Mcleod, MPH3, Melissa McCart, PharmD, MS4 and Apryl Quillen, MS3, (1)US Medical Affairs, Neurology, Bayer HealthCare Pharmaceuticals, Whippany, NJ, (2)US Health Economics and Outcomes Research, Bayer Healthcare Pharmaceuticals, Whippany, NJ, (3)Prospective Research, Xcenda, LLC, Palm Harbor, FL, (4)Global Health Economics and Outcomes Research, Xcenda, LLC, Palm Harbor, FL |